Organisation paid for research Program year 2022 Source: CMS Open Payments

Buynak Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$783,408

535 payments

Through program year 2022, Buynak Clinical Research is reported as receiving $783,408 in research payments, across 535 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $26,645 5
2021 Research $216,492 140
2020 Research $250,559 239
2019 Research $289,713 151

Breakdown

Who paid Research payments · program years 2019–2022
  1. Novo Nordisk AS $421,565 484 payments
  2. Pfizer Inc. $142,416 25 payments
  3. AstraZeneca Pharmaceuticals LP $127,711 8 payments
  4. Lexicon Pharmaceuticals, Inc. $30,018 1 payment
  5. AstraZeneca UK Limited $28,590 2 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $26,576 8 payments
  7. Amgen Inc. $6,533 7 payments
Studies the money was for Research payments · program years 2019–2022
  1. Ex9536-4388 $173,038 313 payments
  2. A 26Week Phase 2B 2Part Randomized Doubleblind Placebo Controlled Parallel Group Doseranging Study to Evaluate the Efficacy and Safety of Pf06882961 Administration in Adults With Obesity $130,000 20 payments
  3. Nn1250-4252 $123,675 8 payments
  4. Nn9535-4321 $100,894 154 payments
  5. A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia $92,920 8 payments
  6. Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $63,380 2 payments
  7. Efc-14875 $30,018 1 payment
  8. A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder $26,576 8 payments
  9. Nn1218-4113 $23,958 9 payments
  10. A 16Week Phase 2B Randomized Doubleblind Placebocontrolled Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Pf06882961 Administration in Adults With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Or Diet and Exercise $12,306 4 payments
What the money was spent on Research payments · program years 2019–2022
  1. Other $26,576 8 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record